3M sheds pharma unit for $2.1 billion

3M has agreed to sell-off its global pharmaceuticals business, which makes dermatology, women’s health, cardiology and respiratory treatments, for $2.1 billion. The 3M Pharmaceuticals division’s most well-known brands include Aldara for the treatment of genital warts, Maxair Autohaler for asthma and MetroGel-Vaginal, indicated in the treatment of bacterial vaginosis. The sell-off of the unit will take place in a three-part transaction, 3M said. Graceway pharmaceuticals will acquire 3M’s pharmaceutical operations in the US, Canada and Latin America for $875 million. Swedish drugs group Meda said it would buy 3M’s pharmaceutical business in Europe for $857 million. Australian private equity firms Ironbridge Capital and Archer Capital agreed to acquire 3M’s pharma operation in the Asia-Pacific region, including Australia and South Africa, for $349 million. Of the 1,050 employees in the division, about 70% would receive employment opportunities with the acquiring companies, 3M said. Sales at the 3M unit were flat in 2005 at $4 billion. In April, 3M said it was exploring the sale of its drugs business, stating its growth would be better suited to the direction of a “dedicated pharmaceutical industry company.”

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions